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The bleomyein assay measures non-traasferrin-bound iron, able to catalyze free radical reactions, inhuman plasma. No bleomycin-detectable iron 
is present inplasma from health~, adults, However, plasma from 3/15 premature babies was positive in this assay. Plasma from 52 apparently-healthy 
term babies was analyzed and 11 ~"¢~r~ositive in the bleomycin assay. Hence not only some premature but also some fall-term apparently-healthy 
. babies may be at risk of severe oxidative damage. 
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1. INTRODUCTION 
Oxygen-derived species such as superoxide radical 
((2).,-) and hydrogen peroxide (H202) are continuously 
generated in the human body and may sometimes serve 
useful physiological roles (reviewed in [1]). Danger can 
arise when these species are brought into contact with 
'free' transition metal ions. In particular, 'catalytic' iron 
ions can convert 02- and H202 into highly-reactive hy- 
droxyl radicals and other damaging species. Iron can 
also accelerate the free radical chain reaction of lipid 
peroxidation [1,2]. Thus the antioxidant defences of the 
human body include not only enzymes that scavenge 
oxygen-derived species (superoxide dismutases, cata- 
lases, glutathione poroxidascs), and inhibitors of lipid 
peroxidation (~-toeopherol), but also proteins, such as 
transferrin and lactoferrin, that sequester i on in 'safe' 
forms that will not catalyze free radical reactions and 
are generally unavailable to most species of bacteria 
[1,3-6]. Thus adult humans have only about 20-30% 
iron loading of plasma transferrin, and their plasma 
does not contain any iron ions available to catalyze tree 
radical reactions [7]. 
Although these conclusions about human iron me- 
tabolism are well-established for adults, iron biochemis- 
try in neonates may be different [8,9]. There are several 
reports that neonates, particularly pro-term, have com- 
promised antioxidant defences, such as low activities of 
antioxidant enzymes [10] and low concentrations of to- 
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copherols [11]. Thus it has been suggested that free 
radical activity is responsible for lung damage (e.g. 
bronchopulmonary dysplasia) in pre-term neonates 
[10,12] and may correlate with the chances of poor out- 
come [13]. Several reports also suggest hat 'free' iron 
may be more available in pre-term neonates [8,934]. 
For example, in a study of rhesus haemolytic disease, 
Berger et al. [15] found that cord blood of babies with 
this disease had lower levels of iron-binding capacity 
and plasma ascorbic acid. Holton et al. [16] found that 
blood transfusions in the pre-term neonate were associ- 
ated with a rise in transferrin saturation and, in some 
cases, transferrin was completely saturated. None of 
these authors measured non-transferrin-bound plasma 
iron directly, however. 
Iron 'catalytic' for free radical reactions can be meas- 
ured in plasma by the bleomycin assay introduced by 
Gutteridge t al. [7,17]. The 'free' iron ions are chelated 
by bleomycin and used to catalyze free radical damage 
to DNA, measured by a colorimetric reaction. The ble- 
omycin assay can be applied directly to plasma samples 
and differences in the levels of  antioxidants present do 
not alTect it [7,17]. For example, the assay has been used 
to follow the progress of patients with iron overload 
consequent upon idiopathic haemochromatosis [18], to 
demonstrate iron overload caused by chemotherapy of
patients with acute myeloid leukaemia [19] and to study 
recovery of normal iron metabolism after liver trans- 
plantation of patients with fulminant hepatic failure 
[20]. 
in the present paper, we have used the bleomycin 
assay to investigate directly previous uggestions [15,16] 
that the plasma of pre-term neonates may contain non- 
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transferrin-bound iron. Plasma from healthy term neo- 
nates was used as a control: this control has not been 
carried out in previous studies, and the results were 
surprising. 
2. SUBJECTS AND METHODS 
The projeot was approved by the Hospital Ethical Committees, Two 
groups of babies were studied: 15 neonates admitted to the Special 
Care Baby Unit (SCBU)during the first 5 days of life (0.80-3,51 kg; 
25--43 weeks gestation) and 52 apparently-normal term controls at 
birth (not requiring admission to SCBU and not receiving any blood 
transfusion), 
Neonates on the SCBU were sampled only at times when blood was 
being drawn for clinical purposes. Only small blood samples (< 1 ml) 
could be taken due to the low blood volume of neonates, Hence the 
study was designed as a random sample, most of the pre-term neonates 
being sampled only once, 
In the second group (term babies), arterial blood was taken from 
the placenta within 2 mix of delivery; APGAR score and arterial pl-[ 
were also measured to give some indication of the degree of pcripar- 
turn distress, if any. APGAR score is a simple clinical assessment of
well-being based on respiration, heart rate, colour, muscle tone and 
reflex response, The maximum score is 10. 
Bleomycin-detcctable ironwas measured as de~ribed in[17l, using 
iron-free plastic materials throughout, Blood was drawn into hepar- 
inized containers, cells removed by ccntrifugation and the plasma 
immediately frozen to -70°C for transportation on dry.ice (total stor- 
age time <14 days, which has no effect on the parameters measured). 
Transferrin iron saturation was measured by 6 M uma/poly- 
acrylamide gel clcctrophol'csis after pre-treatment of samples with 
Rivanol [21l. 
3. RESULTS 
The results from the babies admitted to the SCBU 
and sampled during the first 5 days of life are given in 
Table I, in ascending order of birth weight. Three out 
of 15 showed the presence of bleomycin-detectable iron 
in their plasma. For two of these, plasma transferrin 
analysis showed 100% iron loading of this protein. In- 
sufficient sample was available for this measurement to 
be performed on the third baby (Code .IN). None of 
these babies had received blood transfusions. One other 
sample (CW) showed fully-saturated transferrin, but no 
bleomycin-detectable iron-this baby had received 
blood transfusion because of haemolysis. None of the 
neonates weighing >1.5 kg at birth (8 out of 15) were 
found to have bleomycin-detectable iron in their 
plasma. 
Table II shows the results obtained by analyzing 
plasma from 27 term control babies. We were surprised 
to find that five showed bleomycin-detectable iron in 
their plasma. They did not appear any different from 
the other normal babies in terms of APGAR score at 
5 rain after birth, or arterial blood pH at birth. For two 
of these babies, transferrin was 100% saturated and for 
another two, saturation was >50%. For one baby (Code 
TI), saturation was <50%. 
Because these results were so surprising, we obtained 
a further 25 term baby cord blood plasma samples. Six 
of these were positive in the bleomycin assay, with val- 
ues of 2.1, 1.6, 0.9, 0.9, 0.7 and 0.65/~M. Blood pH 
values and APGAR scores were again normal. Plasma 
samples from healthy human adults analyzed with the 
same batch of reagents howed no bleomycingletectable 
iron, as expected [7,17,18-20]. 
Table I
Plasma iron parameters of babies admitted to the special care baby unit 
Ke 2 to clin[calproblem at the time of sampling: V = positive pressure ventilation; J = significant jaundice (requiring phototherapy); T = haemolysis 
requiring blood transfusion; A = recen t asphyxia; NIL = no clinical problems other than low birth weight. K¢), to transferrin saturation dat~:- = not 
done (insufficient plasma sample available); U = not fully saturated; S = fully 000%) saturated. 
Samples first 5 days of life 
Patient code Birth weight (kg) Gestation (weeks) Age (days) Problem Bleomycin iron Tf saturation 
(umol/l) 
AC 0.80 25 1 V,J 0 
OA 0,80 25 2 V 0 tl 
CHF 0.83 28 4 V 0 U 
RC 1.25 28 3 V,J 2.1 S 
SR 130 30 l A 1.8 S 
CW 1.43 32 3 V,T 0 S 
JN l,$ 31 1 A.V 0.4 - 
GL 1.78 32 3 V 0 U 
GL 1.78 32 $ V 0 U 
DW 1.82 30 2 V 0 - 
MOB 2.04 34 0 NIL 0 U 
MTB 2,07 34 0 NIL 0 U 
SZ 2.3 34 0 NIL 0 U 
MT 2.3 36 i V 0 U 
JM 3.1 38 4 V 0 - 
FC 3.51 43 2 V 0 U 
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Table II 
Plasma iron parameters ofterra control babies 
Patient Blcom)'cin Blood pH APGAR Tra~sferrin 
iron ~umol,'l) score at saturation (%) 
5 rain 
wY 0.85 7.329 9 100 
BU 0.65 7.476 9 >50 
AL 0.5 7.281 7 100 
TI 0.4 7.307 9 <50 
FR 0.35 7.305 9 >50 
PR 0 7.316 9 >50 
CU 0 %260 9 >50 
CR 0 7.188 9 >50 
RA 0 7.408 9 >50 
CC 0 7,104 9 >50 
TL 0 7.340 10 >50 
BL 0 7.321 9 >50 
LU 0 7.345 9 >50 
NE 0 7.449 9 >50 
PH 0 7.307 8 >50 
as 0 7,316 9 <50 
HU 0 7.252 9 <50 
GI 0 7.327 9 <50 
Me 0 7.308 9 <50 
PA 0 7.338 9 <50 
GR 0 7.268 4 <50 
CH 0 7.309 9 <50 
HA 0 7.355 5 <50 
PE 0 7.154 8 <50 
HR 0 7,344 I0 <50 
BA 0 7.311 I0 <50 
KA 0 7.195 9 ,:50 
4. D ISCUSSION 
This  paper reports tile first direct demonstrat ion of 
the presence of bleomycin-detectable iron in the plasma 
of neonates. Its presence in some pre-term neonates is 
consistent with earlier studies [8,9,15,16]. F rom our 
small random sampling during the first 5 days of  life, 
the chance of finding bleomycin-detectable iron in a 
ventilated pre-term neonate weighing 1,5 kg or less ap- 
pears to be of the order o f  1-in-2 to 1-in-3. 
However,  a more surprising finding in our paper is 
the occurrence of  bleomycin-deteetable iron in the 
plasma of  some apparently-healthy term neonates with 
good APGAR scores and approximately normal 
plasma pH. Our data suggest hat iron metabol ism in 
neonates may often be different from that in adults. The 
origin of  the bleomycin-detectable iron is unknown. The 
presence o f  'free' iron in the plasma of  some neonates 
might mean that they are especially susceptible to dam- 
age by infection. First, the 'free' iron could facilitate 
bacterial growth [6]. Second, phagocytes activated by 
bacteria release Oz- and H:O: [22], which can form 
highly-damaging OH'  in the presence o f  catalytic iron 
ions. The babies might also be abnormally-susceptible 
to damaging side-effects f rom drugs whose metabolism 
generates O:- and H,.O2 (many drugs are metabolized 
to free radical products [1]). In addit ion, several food 
additives might cause damaging free radical reactions 
in the presence of  'catalytic' iron [23]. Exposure o f  pre- 
mature neonates to hyperoxia in the SCBU may also 
impose an oxidative stress that could be exacerbated by 
the presence of  'catalytic' iron [14,24]. 
It was also interesting to note the presence of bleomy- 
t in.detectable iron in some term babies, despite the co- 
existence of  transferrin iron-binding capacity. Such an 
observation has previously been made in iron.over- 
loaded patients after venesection treatment [18]. It may 
be that the iron exists as chelates that are poor donors  
of iron to transferrin [18]. In any case, further studies 
upon iron metabolism in premature and full-term ba- 
bies in relation to their prospective health and survival 
seem urgently required. 
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